T1	Participants 569 634	T1DM patients on continuous subcutaneous insulin infusion (CSII).
T2	Participants 817 883	Twenty-eight patients were randomized and exposed to trial product
T3	Participants 1801 1855	insulin absorption with less intra-subject variability
